Acute Myeloid Leukemia (AML)

What have we learned about TP53-mutated acute myeloid leukemia?

Original Publication Date
Article Source
External Web Content
Abstract TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally associated with poor outcomes. TP53 mutations are found in approximately 5% to 10% of patients with de novo acute myeloid leukemia (AML), more frequently observed in elderly patients and…

Trent Peng Wang, DO

Institution
University of Miami Health System - Sylvester Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Dr. Trent Wang is an Associate Professor of Clinical Medicine within the Division of Transplantation and Cellular Therapy. Since joining Sylvester Comprehensive Cancer Center, his clinical focus has been treating patients with hematologic cancers who require allogeneic hematopoietic stem cell transplantation and other cellular therapies. Dr. Wang's research focuses on complications of allogeneic hematopoietic stem cell transplantation, including conducting interventional, behavioral and retrospective studies of graft-versus-host disease, infectious transplant complications, and transplant

Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial

Original Publication Date
Article Source
External Web Content
Summary Background Access to allogeneic haematopoietic stem-cell transplantation (HSCT) remains challenging for older patients (aged >60 years) with acute myeloid leukaemia. We aimed to evaluate the efficacy of venetoclax plus decitabine as first-line therapy and bridge to…

Mariam Nawas, MD

Institution
University of Chicago
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)

Michael Drazer, MD, PhD

Institution
University of Chicago
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Michael Drazer, MD, PhD, is a hematologist/oncologist and geneticist specializing in the care of people with blood disorders, blood cancers, hereditary blood disorders, and hereditary cancer syndromes. He runs one of the only clinics in the world focused on the care of people with hereditary blood cancer syndromes. Dr. Drazer's laboratory research focuses on determining the mechanisms that drive hereditary blood and cancer syndromes, with a particular emphasis on developing "high fidelity" cellular and mouse models of these disorders. He is also heavily involved in the discovery of novel
Subscribe to Acute Myeloid Leukemia (AML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.